Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (771)	1/6/2007 1:59:46 AM
From: tuck	Read Replies (1) \| Respond to of 933

I'd like to think the incoherence in that piece was due to the AP writer, and that Michael King is much less clueless. Undervalued due to management mistakes . . . well, I've seen worse, really. Kosan is not yet in the class of CTIC, TELK, BLSI. Could have done with less insider selling at this stage. EPO D might not make it, but they got some funds out of Roche before finding out its problems. Am I forgetting/missing other mistakes? "the company should continue to lose money?" Sheesh, I can write better than that drunk. Cheers (Hic), Tuck